Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of oral pharmaceutical composition for treating diabetes

A technology for diabetes and composition, which is applied in the field of oral pharmaceutical compositions for treating diabetes, can solve the problem that there is no literature report on the anti-diabetic activity of kava kava kava

Active Publication Date: 2020-10-09
王磊
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No literature has reported the antidiabetic activity of kava and its active ingredient, kavaperine B

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of oral pharmaceutical composition for treating diabetes
  • A kind of oral pharmaceutical composition for treating diabetes
  • A kind of oral pharmaceutical composition for treating diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Embodiment 1 The granule for treating diabetes and its preparation

[0027]

[0028] Preparation:

[0029] A: Take kavaperine B and pimavanserin tartrate and pass through a 100-mesh sieve, and mix well.

[0030] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. which milk

[0031] The amount of sugar used is 2.0 times the weight of kava B; the amount of microcrystalline cellulose is 1.2 times the weight of kava B; the amount of crospovidone is 0.12 times the weight of kava B

[0032] C: Mix the powder obtained in step A and step B evenly.

[0033] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. The dosage of povidone K30 is 0.17 times of the weight of kavaperine B; the dosage of water is 32.3 times of the weight of povidone K30.

[0034] E: The liquid dispersion system obtained in step D is added to the powder obtained in step C, granulated, dried, and the dry partic...

Embodiment 2

[0036] Example 2 Granules for treating diabetes and its preparation

[0037]

[0038] Preparation:

[0039] A: Take kavaperine B and pimavanserin tartrate and pass through a 100-mesh sieve, and mix well.

[0040] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. which milk

[0041] The amount of sugar used is 2.0 times the weight of kava B; the amount of microcrystalline cellulose is 1.2 times the weight of kava B; the amount of crospovidone is 0.12 times the weight of kava B

[0042] C: Mix the powder obtained in step A and step B evenly.

[0043] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. The dosage of povidone K30 is 0.17 times of the weight of kavaperine B; the dosage of water is 32.3 times of the weight of povidone K30.

[0044] E: The liquid dispersion system obtained in step D is added to the powder obtained in step C, granulated, dried, and the dry particles ar...

Embodiment 3

[0046] Embodiment 3 granule for treating diabetes and its preparation

[0047]

[0048] Preparation:

[0049] A: Take kavaperine B and pimavanserin tartrate and pass through a 100-mesh sieve, and mix well.

[0050] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. which milk

[0051] The amount of sugar used is 2.0 times the weight of kava B; the amount of microcrystalline cellulose is 1.2 times the weight of kava B; the amount of crospovidone is 0.12 times the weight of kava B

[0052] C: Mix the powder obtained in step A and step B evenly.

[0053] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. The dosage of povidone K30 is 0.17 times of the weight of kavaperine B; the dosage of water is 32.3 times of the weight of povidone K30.

[0054] E: The liquid dispersion system obtained in step D is added to the powder obtained in step C, granulated, dried, and the dry particles ar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicine, and particularly relates to an oral pharmaceutical composition for treating diabetic. The oral pharmaceutical composition is prepared from, by weight, pharmaceutically acceptable excipients, 11-23 parts of kava piperine B and 5-10 parts of tartaric acid pimavanserin. The oral pharmaceutical composition is granules preferably. Animal experiments showthat a compound of kava piperine B and tartaric acid pimavanserin has good antidiabetic effect and safety.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to an oral pharmaceutical composition for treating diabetes. Background technique [0002] Diabetes mellitus is a chronic, complex metabolic disease characterized by abnormal glucose metabolism and pathological elevation of blood sugar, and is a type of disease caused by relative or absolute insulin deficiency. At present, diabetes has become one of the three major chronic non-communicable diseases that threaten human health. There are more than 92.4 million diabetic patients in China aged 20-79, accounting for about 1 / 4 of the total number of patients in the world, and the prevalence rate is increasing and younger. For a long time to come, diabetes will remain one of the major diseases that will increase the burden of medical care. [0003] With the gradual deepening and expansion of basic research, in addition to traditional antidiabetic drugs such as insulin, sulfonylureas, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/12A61K31/4468A61K9/16A61P3/10
CPCA61K9/1652A61K31/12A61K31/4468A61K2300/00
Inventor 王磊崔丽媛吕范凯
Owner 王磊
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com